Henoch-Schönlein purpura (HSP) during treatment with anastrozole.
Conti-Beltraminelli
M
M
Institute of Oncology of Southern Switzerland (IOSI), Ospedale Regionale Bellinzona e Valli, Switzerland.
Pagani
O
O
Institute of Oncology of Southern Switzerland (IOSI), Ospedale Regionale Bellinzona e Valli, Switzerland. Electronic address: olivia.pagani@ibcsg.org.
Ballerini
G
G
Institute of Oncology of Southern Switzerland (IOSI), Ospedale Regionale Bellinzona e Valli, Switzerland.
Richetti
A
A
Institute of Oncology of Southern Switzerland (IOSI), Ospedale Regionale Bellinzona e Valli, Switzerland.
Graffeo
R
R
Institute of Oncology of Southern Switzerland (IOSI), Ospedale Regionale Bellinzona e Valli, Switzerland.
Ruggeri
M
M
Institute of Oncology of Southern Switzerland (IOSI), Ospedale Regionale Bellinzona e Valli, Switzerland.
Forni
V
V
Division of Nephrology, Ospedale Regionale di Lugano.
Pianca
S
S
Division of Nephrology, Ospedale Regionale di Lugano.
Schönholzer
C
C
Division of Nephrology, Ospedale Regionale di Lugano.
Mainetti
C
C
Division of Dermatology, Ospedale Regionale Bellinzona e Valli, Switzerland.
Cavalli
F
F
Institute of Oncology of Southern Switzerland (IOSI), Ospedale Regionale Bellinzona e Valli, Switzerland.
Goldhirsch
A
A
Institute of Oncology of Southern Switzerland (IOSI), Ospedale Regionale Bellinzona e Valli, Switzerland.
D000368:Aged; D000077384:Anastrozole; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D011695:IgA Vasculitis / Q000139:chemically induced* / Q000473:pathology; D009570:Nitriles / Q000009:adverse effects*; D014230:Triazoles / Q000009:adverse effects*
D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole